Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab
Receptors, Antigen, T-Cell, gamma-delta
High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 1-10. ©2016 AACR.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency